RxDoctor Payments Data

Lindsey Pennington

Facial Plastic Surgery · Shreveport, LANPI 1134411507

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $374,825 of the $420,220 with a category attached, or 89.2%. AbbVie accounts for 79.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $163,225 and has fallen 70.8% since, to $47,705 in 2025.

$420,220in general payments, 2019–2025

Across 497 payments — averaging $845.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$335K
  • Galderma Laboratories, L.p.$85K
  • Revance Therapeutics, Inc.$95
  • Merz North America, Inc.$87
  • Dutch Ophthalmic, USA$26

What the payments were for

  • Consulting fees$11,4003%
  • Speaking & faculty fees$374,82589%
  • Travel & lodging$25,8796%
  • Food & beverage$8,0722%
  • Education$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few facial plastic surgery providers in Louisianato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib12$363
Cephalexin11$214
ValacyclovirValacyclovir Hcl17$177
Ondansetron OdtOndansetron13$158
Mupirocin15$142

Paid to pharmacies, not to this prescriber.

Other facial plastic surgery in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →